NO942515L - Fremgangsmåte for fremstilling av preparater for vedvarende frigiving - Google Patents

Fremgangsmåte for fremstilling av preparater for vedvarende frigiving

Info

Publication number
NO942515L
NO942515L NO942515A NO942515A NO942515L NO 942515 L NO942515 L NO 942515L NO 942515 A NO942515 A NO 942515A NO 942515 A NO942515 A NO 942515A NO 942515 L NO942515 L NO 942515L
Authority
NO
Norway
Prior art keywords
water
soluble polypeptide
preparation
sustained release
release preparations
Prior art date
Application number
NO942515A
Other languages
English (en)
Other versions
NO942515D0 (no
Inventor
Yasutaka Igari
Kazumichi Yamamoto
Kayoko Okamoto
Yutaka Yamagata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO942515D0 publication Critical patent/NO942515D0/no
Publication of NO942515L publication Critical patent/NO942515L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det blir beskrevet en fremgangsmåte for fremstilling av et preparat for vedvarende frigiving som omfatter å la et vannoppløselig polypeptid impregnere inn i en biodegraderbar matriks i vandig opplesning. Fremgangsmåten for produksjon ifølge foreliggende oppfinnelse, muliggjør impregneringen av et vann- oppløselig polypeptid inn I en biodegraderbar matriks uten å bringe det vannoppløselige polypeptidet i kontakt med et organisk oppløsnlngsmlddel . Det vannoppløsellge polypeptidet blir således preparert uten å påvirke det vannoppløsellge polypeptidets bloaktivltet, og er således effektiv for anvendelse som et farmasøytika.
NO942515A 1993-07-05 1994-07-04 Fremgangsmåte for fremstilling av preparater for vedvarende frigiving NO942515L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16579393 1993-07-05
JP8176594 1994-04-20

Publications (2)

Publication Number Publication Date
NO942515D0 NO942515D0 (no) 1994-07-04
NO942515L true NO942515L (no) 1995-01-06

Family

ID=26422772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942515A NO942515L (no) 1993-07-05 1994-07-04 Fremgangsmåte for fremstilling av preparater for vedvarende frigiving

Country Status (11)

Country Link
US (1) US5534269A (no)
EP (1) EP0633020B1 (no)
KR (1) KR950002748A (no)
CN (1) CN1106653A (no)
AT (1) ATE184480T1 (no)
AU (1) AU674077B2 (no)
CA (1) CA2127317C (no)
DE (1) DE69420632T2 (no)
FI (1) FI943205A (no)
NO (1) NO942515L (no)
NZ (1) NZ260909A (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
CA2224381A1 (en) * 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
DE69717263T2 (de) * 1996-03-28 2003-07-24 Takeda Chemical Industries, Ltd. Zubereitung mit verzögerter freisetzung und deren herstellung
AU7871298A (en) 1996-12-20 1998-07-17 Takeda Chemical Industries Ltd. Method of producing a sustained-release preparation
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
KR100595340B1 (ko) * 1998-01-21 2006-07-03 다케다 야쿠힌 고교 가부시키가이샤 서방형 제제의 동결 건조법
KR20010042079A (ko) 1998-03-20 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 생리학적으로 활성인 폴리펩티드의 서방 제제 및 그것의제조 방법
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
WO2001017542A1 (fr) 1999-09-08 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Preparation de solution de proteines et procede de stabilisation associe
AU7313400A (en) 1999-09-17 2001-04-24 Takeda Chemical Industries Ltd. Process for producing protein powder
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
AU8260701A (en) * 2000-09-01 2002-03-13 Chugai Pharmaceutical Co Ltd Solution preparations stabilized over long time
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
US7318931B2 (en) 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CA2471521C (en) * 2001-12-26 2010-11-02 Takeda Chemical Industries, Ltd. Novel microsphere and method for production thereof
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
AU2004253853B2 (en) * 2003-04-10 2010-04-01 Evonik Corporation A method for the production of emulsion-based micro particles
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2004091723A1 (en) * 2003-04-15 2004-10-28 Opperbas Holding B.V. Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
ES2625343T3 (es) * 2003-07-15 2017-07-19 Evonik Corporation Método para la preparación de formulaciones de liberación controlada
CN100588423C (zh) * 2003-07-23 2010-02-10 Pr药品有限公司 控释组合物
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE102004046102B4 (de) * 2004-09-23 2009-09-03 Mars Inc. Indikatorgranulat
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101199623B (zh) * 2006-12-16 2011-04-27 石茂光 治疗高血压药物缓控释制剂的制备方法
CN103007288B (zh) 2007-05-18 2015-02-11 杜雷科特公司 改进的贮库制剂
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
WO2014164754A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104288123B (zh) * 2014-10-27 2016-09-14 浙江理工大学 一种负载干扰素微胶囊的制备方法
CN110404115B (zh) * 2019-07-23 2022-03-18 广东省医疗器械研究所 一种具有表面坑洞的碳酸盐/可降解高分子微球及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles

Also Published As

Publication number Publication date
US5534269A (en) 1996-07-09
FI943205A0 (fi) 1994-07-05
AU6614594A (en) 1995-01-12
EP0633020A1 (en) 1995-01-11
EP0633020B1 (en) 1999-09-15
CN1106653A (zh) 1995-08-16
NZ260909A (en) 1995-04-27
DE69420632T2 (de) 2000-03-02
KR950002748A (ko) 1995-02-16
AU674077B2 (en) 1996-12-05
DE69420632D1 (de) 1999-10-21
CA2127317C (en) 2008-10-07
CA2127317A1 (en) 1995-01-06
ATE184480T1 (de) 1999-10-15
FI943205A (fi) 1995-01-06
NO942515D0 (no) 1994-07-04

Similar Documents

Publication Publication Date Title
NO942515L (no) Fremgangsmåte for fremstilling av preparater for vedvarende frigiving
CA2126685A1 (en) Process for the production of microcapsules
ATE101340T1 (de) Neue arzneimittelformulierung sowie verfahren zu deren herstellung.
DK629388D0 (da) Fremgangsmaade til fremstilling af amphotericin b liposome
DK0580817T3 (da) Farmaceutisk præparat og fremgangsmåde til fremstilling deraf
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
PT78711A (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
RU93005051A (ru) Способ получения катионных кристаллов гр или производных гр, катионные кристаллы человеческого гр или производных человеческого гр, фармацевтические препараты, использование процесса кристаллизации
DE69904701D1 (de) Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
EP0761210A3 (de) Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
ATE151643T1 (de) Lanolinderivate als penetrationsfördernde substanzen
ATE142267T1 (de) Verfahren zur herstellung von gamma- und delta- lactonen
ATE116636T1 (de) Verfahren zur herstellung von 2,6- dichlordiphenylaminessigsäurederivaten.
ATE167871T1 (de) Verfahren zur herstellung von vancomycin
DE3852577D1 (de) Verfahren zur Herstellung von Dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1b]furan und von Haloethyldecalin-Derivaten.
KR970706231A (ko) 사이클로프로판카복실산 및 그 유도체의 제조방법(processes for the preparation of cyclopropanecarboxylic acid and derivatives thereof)
DE68912236D1 (de) Verfahren zur Herstellung von hochgradig ungesättigten Fettsäuren.
DE69002568D1 (de) Verfahren zur herstellung von optisch aktiven 2-arylpropionsaeuren.
ATE56699T1 (de) Verfahren zur herstellung von gamma-butyrobetain.
ATE135369T1 (de) Chemisches verfahren zur herstellung des antibiotikums l 17392 (deglukoteicoplanin) und dessen salze
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
AU629008B2 (en) Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
ATE94766T1 (de) Verfahren zur herstellung einer galenischen zubereitung mit optimaler bioverfuegbarkeit des wirkstoffs 2-hydroxy-5-methyllaurophenonoxime (hmlo).
DE68928788D1 (de) Verfahren zur Herstellung von optisch aktiven 3,4-Dihydroxybuttersäurederivaten
DE59001456D1 (de) Verfahren zur herstellung von 1,3-cyclopentandion.